Clinical Trial Update: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating a three-drug combination of obinutuzumab, ibrutinib, and venetoclax for previously untreated stage II-IV foll…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: University of California, Davis | Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING